Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.34 |
| ▸ | KCNQ4 | P56696 | 3/20 | 0.33 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292362 | 0.88 | AKT1 (0.38) | AKT1AAK1KCNQ4KCNQ5 | |
| SCHEMBL293844 | 0.84 | AKT1 (0.47) | AKT1AAK1KDM4ECTSS | |
| SCHEMBL292617 | 0.80 | AKT1 (0.41) | AKT1AAK1CTSSCTSK | |
| SCHEMBL292353 | 0.77 | AKT1 (0.44) | AKT1AAK1CTSSCTSK | |
| SCHEMBL291831 | 0.76 | AKT1 (0.46) | AKT1AAK1SSTR4CTSS | |
| SCHEMBL291873 | 0.76 | AKT1 (0.53) | AKT1AAK1CTSSCTSK | |
| SCHEMBL291187 | 0.74 | AKT1 (0.50) | AKT1BRD4KDM4ECTSS | |
| SCHEMBL292041 | 0.72 | MAPT (0.43) | AAK1SSTR4BRD4 | |
| SCHEMBL33525705 | 0.67 | AAK1 (0.41) | AAK1KCNQ4KCNQ5CTSSCTSK | |
| SCHEMBL27398698 | 0.65 | MAPT (0.51) | KCNQ4KCNQ5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158790-B2 | Cyclic amine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2036896-B1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | AKT1 2749/4885AAK1 3037/4885KCNQ4 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.